- CEO
- Jonathan Stewart Murphy
- Full Time Employees
- 84
- Sector
- Real Estate
- Industry
- REIT - Healthcare Facilities
- Address
- The Brew House Warrington United Kingdom WA4 6HL
- IPO Date
- Jan 8, 2021
- Business
- Assura Plc (AGR) is the United Kingdom's leading owner and operator of primary healthcare properties, functioning as a healthcare real estate investment trust (REIT) focused on investing in, developing, and managing medical facilities leased primarily to general practitioners, health professionals, and the National Health Service (NHS). The company offers a portfolio exceeding 600 properties, including general practitioner surgeries, primary care centers, diagnostic and treatment facilities with x-ray services, renal dialysis units, MSK physiotherapy clinics, dentistry practices, acute consultant clinics, and community-based social prescribing services, all designed to support NHS community healthcare delivery. These assets, valued at approximately GBP 2.7 billion as of March 2024 with 614 medical centers, generate stable rental income predominantly from long-term NHS leases, over 90% of which are inflation-linked.
Founded in 2003 and headquartered in Altrincham, Greater Manchester, Assura Plc operates exclusively within the UK healthcare property sector, targeting primary care infrastructure to meet growing demand for community-based services amid NHS shifts toward decentralized care. The company maintains a subsidiary structure including Assura Financing Plc for investment holding activities and has historically pursued development pipelines, committing to around GBP 200 million in new builds over multi-year periods while acquiring additional properties to expand its footprint.
In a transformative development, Assura Plc was acquired by Primary Health Properties Plc (PHP) in August 2025 following shareholder approval on August 12 and deal completion on August 15, creating a combined GBP 6 billion healthcare REIT with enhanced scale for infrastructure investment across the UK and Ireland. This transaction, valued at approximately GBP 1.68 billion and cleared by the UK Competition and Markets Authority (CMA) in Phase 1 review by late October 2025, enables projected run-rate cost synergies of at least GBP 9 million annually and supports accelerated expansion with a lower cost of capital. Prior to the acquisition, Assura engaged in strategic disposals totaling GBP 200 million, including seven healthcare assets for GBP 64 million in early 2025, and navigated competing bids from KKR & Stonepeak before recommending PHP's offer.